Article Sidebar

PDF
Date Published: 11/07/2022
Online Published: 11/07/2022
Abstract Views: 88
Views PDF: 87
DOI: https://doi.org/10.55046/vjrnm.9.269.2012
Issue
No. 9 (2012)
Section
Scientific research
How to Cite
Bui, Q. H., & Nguyen, D. H. (2022). Compare MRI and PET/CT in cancer diagnosis through literature. Vietnamese Journal of Radiology and Nuclear Medicine, 9, 324-330. https://doi.org/10.55046/vjrnm.9.269.2012

Compare MRI and PET/CT in cancer diagnosis through literature

Bui Quang Huynh1, Nguyen Duy Hue1,
1 Viet Duc Hospital

Main Article Content

Abstract

SUMMARY


This paper aims to compare the ability of MRI and PET/CT in the diagnosis of cancer, assessment of tumor stages according
to TNM classification, the advantages and disadvantages of each method through literature. The results showed that PET/CT has the advantages in the assessment of tumor stage (T) and the status of lymph nodes, especially with lung or head/neck primary tumors. However, the disadvantages of PET/CT are the high radiation exposure and the expensive cost. Whole body MRI has a high accuracy in the detection of distant metastases especially in bone, liver and central nervous system. MRI is considered as the first choice in the primary tumors which have bad FDG fixation such as renal cell and prostate carcinoma. Additionally, MRI is very good at the accurate evaluation of the entire skeleton condition and highly effective in the stage assessment of malignant bone marrow diseases.

Article Details

References

TÀI LIỆU THAM KHẢO
1. Antoch G, Vogt FM, Freudenberg LS et al (2003). Whole body dual-modality PET/CT and whole body MRI for tumor stanging in oncology. JAMA 290; 3199-3206.
2. Goerres GW, Michel SCA, Fehr MK et al (2003). Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 13;1635–1644.
3. Hanrahan CJ, Christensen CR, Crim JR (2010). Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. RadioGraphics, 30;127–142.
4. Huang B, Ming Law MW, Khong PL (2009). Whole body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 251 (1); 166 174.
5. Iagaru A, Masamed R, Keesara S et al (2007). Breast MRI and 18F FDG PET/CT in the management
of breast cancer. Annals of Nuclear Medicine Vol. 21, No. 1; 33–38.
6. Imbriaco M, Caprio MG, Limite G et al (2008). Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions. AJR, 191;1323–1330
7. Kitajima K, Murakami K, Kaji Y et al (2010). Spectrum of FDG PET/CT findings of uterine tumors. AJR 195:737–743.
8. Kwee TC, Ufford HMEQ, Beek FJ et al (2009). Whole-body MRI, including Diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 44: 683–690
9. Murphy RC, Kawashima A, Peller PJ (2011). The utility of 11C-Choline PET/CT for imaging prostate
cancer: a pictorial guide. AJR 196:1390–1398.